Dendritic-cell vaccine (DCVAC) with first line chemotherapy in patients with stage IV NSCLC primary analysis of phase 2, open-label, randomized, multicenter trial.
/in Dendritic Cells, NSCLC /von 2018-06-03 / J Clin Oncol 36, 2018 (suppl; abstr 9051)Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with recurrent epithelial ovarian carcinoma (EOC) after complete response (CR) to 1st-line platinum (Pt)-based ct: Primary analysis of a phase 2, open-label, randomized, multicenter trial.
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2018-06-01 / J Clin Oncol 36, 2018 (suppl; abstr e17515)Vaccination of Urological Cancer Patients With WT1 Peptide-Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses
/in Dendritic Cells, Hypernephroma, International Publications, Urothelial Carcinoma /von 2018-05-30 / Ther Apher Dial 2018 Jun;22(3):266-277First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2018-05-29 / J Transl Med 2018 May;16(1):142Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme
/in Dendritic Cells, Glioblastoma, International Publications /von 2018-05-29 / Front Immunol 2018;9:727Dendritic cells loaded with the lysate of tumor cells infected with Newcastle Disease Virus trigger potent anti-tumor immunity by promoting the secretion of IFN-γ and IL-2 from T cells
/in Dendritic Cells, International Publications, Newcastle Disease Virus /von 2018-05-22 / Oncol Lett 2018 Jul;16(1):1180-1188Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer
/in Dendritic Cells, Esophageal Carcinoma, International Publications /von 2018-05-17 / Oncol Lett 2018 Jul;16(1):1348-1356Vaccine therapy in hematologic malignancies
/in Dendritic Cells, International Publications /von 2018-05-04 / Blood 2018 Jun;131(24):2640-2650Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors
/in Dendritic Cells, International Publications /von 2018-05-01 / Vaccine 2018 05;36(23):3247-3253
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de